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ABSTRACT 
Background: The widespread availability of antiretroviral therapy has led to a reduction 
in mortality and morbidity in HIV/AIDS patients in Botswana. However, high levels of 
adherence to antiretroviral drugs are necessary for good virologic and immunologic 
responses which are critical for improved survival. Approximately 100 women who 
initiated highly active antiretroviral therapy (HAART) while pregnant are currently being 
followed in 4 research clinics in Botswana. There is currently no data available on 
adherence among women initiating HAART during pregnancy at these clinics or among 
pregnant women on HAART elsewhere in Botswana. It is critical to study and understand 
the key factors that influence adherence among women receiving treatment at these 
clinics following initiation during pregnancy, to avert or reduce the consequences of 
treatment failure. 
 
Aim: The study aimed to assess the level of adherence and to identify the barriers to 
adherence and the motivations for good adherence to antiretroviral therapy, amongst 
women who commenced treatment while pregnant at research clinics in Molepolole, 
Mochudi, Lobatse and Gaborone. 
 
Study Population and Sample: All women who initiated HAART during pregnancy and 
were currently receiving treatment at the research clinics in Molepolole, Lobatse, 
Gaborone and Mochudi in Botswana. 
 
Method: A quantitative study was conducted using a cross sectional descriptive design. 
Data was collected using a structured questionnaire administered to all women receiving 
standard care HAART at the clinics, during their monthly refill visits between 02 
September and 15th October, 2009. Additional relevant information was extracted from 
participant’s medical records using a data extraction tool. Informed consent was obtained 
from the women who participated in the study prior to administration of the questionnaire 
and subsequent data extraction from their medical records. Data was analysed with SPSS 
version 14 using descriptive and analytic statistics. Adherence was categorized as 
excellent (100%), adequate (≥95%) and inadequate (<95%).  
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Results: A total of 94 women consented to the study and were interviewed across the 4 
sites. The mean CD4 counts at antenatal, immediate post natal and late post natal were 
266, 315 and 346 respectively. Overall adherence of the study participants was good, 
99% had adequate adherence and 67% of the women had excellent adherence using pill 
count over a six month period. Self reported adherence was 100% for 1-day, 3-day and 7-
day recall. Ninety-nine percent (99%) of the subjects received adherence counselling 
before initiating therapy while approximately 33% of the women received counselling at 
every visit. Ninety percent (90%) of the women rated the quality of services received at 
the clinic as very good. Reasons cited for ever missing medications were forgetfulness 
(18%) and not having medications at the time of the dose (13%). The participants had 
high knowledge of ARVs and HIV/AIDS. There was no significant difference in 
adherence during pregnancy, immediately post partum and the late post partum period. 
There was no significant association between adherence and demographic factors, 
socioeconomic factors, quality and adequacy of service provision as well as knowledge 
attitudes and perceptions towards HIV/AIDS and ARVs. Bivariate analysis showed no 
association in this study between the factors usually known to be associated with 
adherence from other studies.  
 
Conclusions: A high level of adherence was observed among the study population, with 
99% achieving adequate adherence of ≥ 95% and 67% maintaining excellent adherence 
of 100% during the period reviewed, however these might be overestimates of actual 
adherence. Even if there is a degree of over-estimation the study still shows a high level 
of adherence among participants in a research cohort who received a higher standard of 
care with consistent and adequate adherence monitoring throughout their duration of care. 
 
Recommendations: Although the study reported a high level of adherence, there is need 
to devise mechanisms of making the medications portable and strengthening mechanisms 
for reminding patients about timing of the doses. As Botswana rolls out universal access 
to HAART among pregnant women in the country, it will be essential to learn from this 
cohort experience so as to attain excellent adherence levels within the general population. 
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CHAPTER 1 
INTRODUCTION, PROBLEM STATEMENT AND PURPOSE 
 
1.0 INTRODUCTION 
HIV/AIDS is a major public health problem. Since the 1980’s when it was first described, 
the spread has been astronomical. More than 33 million people worldwide were living 
with HIV/AIDS at the end of 2007 (UNAIDS, 2008). Worst hit by the recently 
discovered Human Immunodeficiency virus is Sub-Saharan Africa, which accounts for 
two thirds of all people infected with the virus. An estimated 22 million people are living 
with the virus in this region. Approximately 1.9 million new infections and 1.5 million 
deaths were reported in 2007 alone. This region has remained the global epicentre of the 
pandemic. 
 
Botswana had a projected population of 1.74 million in 2007 (CSO, 2001). The country’s 
national HIV prevalence is estimated at 26.9% amongst the 15-49 years age group at the 
end of 2007. Amongst pregnant women of the same age group attending antenatal clinics, 
the prevalence was 33.7% (Ministry of Health, 2007). It is estimated that 275,773 persons 
are living with HIV in the country of which 163, 630 are females and 112,143 are males. 
This is second in the world only to Swaziland in terms of country prevalence. HIV/AIDS 
has remained the country’s most important public health challenge and the biggest threat 
to its development (Ministry of Health, 2007).   
 
With the widespread availability of highly active antiretroviral therapy (HAART) in 
Botswana, there has been a significant improvement in survival for people living with 
HIV/AIDS. A recent analysis of data on HIV/AIDS patients on antiretroviral therapy 
showed an overall 5-year survival rate of 88.8% using Kaplan-Meier estimates (Ministry 
of Health, 2007), but adherence to these medications has been a major concern.  
 
Prevention of mother to child transmission (PMTCT) programmes has been achieving 
tremendous successes in reducing the risk of HIV transmission from infected mothers to 
their infants. Current standard of care in the developed world is the use of triple therapy 
(HAART), which has reduced vertical transmission rates to 1-2% (WHO, 2007). The 
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Botswana ministry of health currently uses mainly Zidovudine monotherapy and single 
dose Nevirapine for their PMTCT programme. HAART is available only to pregnant 
women with a CD4 count of less than 250 or an AIDS defining illness. This combination 
of basic PMTCT, and HAART when indicated, has achieved a reduction in transmission 
rates to <4% (Ministry of Health, 2008). HAART has the added advantages of lowering 
the risk of resistance developing, compared to single or dual therapy, as well as improved 
maternal health outcomes (Mocroft et al., 2004). As the country awaits clinical trials data 
to inform a potential policy change towards universal HAART rollout in pregnancy, an 
important concern is that poor adherence to these combination therapies would be a 
major challenge hindering optimal benefit.  
 
The optimal benefit of HAART includes good virologic and immunologic responses 
critical for decreasing intrauterine and intrapartum transmission, as well as improved 
maternal survival. It also has protective effects during the breastfeeding period leading to 
improved infant survival, if a mother chooses this feeding option (Lockman et al., 2009). 
 
One hundred and seventy HIV positive pregnant women were enrolled in the 
observational arm of a prevention of mother to child transmission study, at research 
clinics located in three peri-urban communities in Botswana, (namely Molepolole, 
Mochudi, Lobatse) and the capital city Gaborone between July 2006 and May 2008. The 
Participants were recruited from amongst women using both public and private sector 
antenatal facilities and were followed up till 02 September, 2010. Table 1.1 below 
provides a description of the study sites. 
 
The 170 women enrolled across the four sites were part of a larger cohort of 730 HIV 
positive pregnant women recruited for a prevention of mother to child transmission study. 
They were enrolled during pregnancy and initiated on highly active antiretroviral drugs 
(AZT/3TC and Nevirapine) according to the Botswana standard of care criteria of 
CD4<200 or presence of an AIDS defining illness (Ministry of Health, 2005). The CD4 
cut-off was revised upwards to 250 in November, 2008 after the study has completed 
accrual (Ministry of Health, 2008). The treatment they received is therefore the same as 
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the standard treatment provided to HIV positive pregnant women, with the same CD4 
count in the public health sector in Botswana. All of them received this treatment 
irrespective of their CD4 counts. They were all requested to attend the research clinics for 
monthly follow up visits and medication refills. The remaining 560 women were 
randomized to receive one of two investigational HAART regimens (Kaletra and 
Combivir or Trizivir). Participants were required to return unused medication to the clinic 
at each visit. During these visits the returned pills were counted and the results were 
compared to the expected number of pills to be returned, based on the number of pills 
dispensed at the last visit. Findings were documented in the study case report forms as 
well as participants specific drug profile, in order to evaluate adherence. The nurses also 
reviewed and filed returned pill calendars which were completed by the participants.  
 
The pill calendar is a prepared single sheet of paper, in the form of a modified monthly 
calendar, that enables subjects to fill in their names, study number, the time they took 
their medication each day and a signature, see appendix 4). Pill calendars were issued 
monthly and returned to the clinic by the participants at each medication refill visit. 
Adherence counselling was done by the nurses at each visit. It involved evaluating the 
challenges each woman faced in taking their medication and seeking ways of solving 
them together. More time was spent with patients with poor adherence whilst praises and 
positive reinforcement were given to those with excellent adherence.  
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Table 1.1: Description of the study sites 
Site Name Location No. of 
rooms in 
the facility 
No. of women in 
the observational 
arm 
No. Doctors No. nurses Counsellors 
Mochudi(Deborah 
Retief  Hospital) 
Peri 
urban 
6 42 1 3 0 
Lobatse (Athelone 
Hospital) 
Peri 
urban 
5 31 1 3 0 
Molepolole(Scotish 
Livingstone 
Hospital) 
Peri 
urban 
8 39 1 4 2 
Gaborone (Princess 
Marina Hospital) 
Urban 5 58 1 3 2 
Total  24 170 4 13 8 
 
There are only a few studies globally on adherence to HAART during pregnancy (Sankar 
et al., 2002; Kingston, Letham and McQuillan, 2007; Bardeguez et al., 2008; Weinberg 
et al., 2009). Although HAART has been used in Botswana among pregnant women who 
are eligible since 2003, I could not find any study on adherence among women who 
initiated HAART during pregnancy in Botswana. A literature search on adherence, 
PMTCT, HAART, dual or monotherapy and Botswana as keywords was conducted using 
PubMed, OmniMedical Search and the Harvard University Library of Medicine. 
However one study has examined qualitatively the barriers to participation in PMTCT 
and completing HIV prophylaxis in Botswana (Kebaabetswe, 2007). The author 
concluded that fear of knowledge of their HIV status, infant formula distribution stigma, 
lack of male partners' support and negative attitudes of health workers, were significant 
barriers to pregnant women participating in the PMTCT programme.   
 
In the general population in Botswana some barriers to adherence that have been 
identified include treatment related costs, lack of privacy, stigma, fear of disclosure and 
cultural beliefs; while facilitators of good adherence include perceived benefits of 
HAART, awareness of consequences of poor adherence and the presence of social 
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support mechanisms (Weiser et al., 2003; Kgatlwane et al., 2006; Kip, 2009).  
It is important to study and understand the key factors that influence adherence at clinics 
initiating HAART in pregnancy, in order to avert or reduce the consequences of treatment 
failure, which includes the use of more complicated and expensive second, third line and 
salvage regimes, transmission of resistant viral mutants and high cost of hospitalization 
and management of opportunistic infections, as well the consequences of increased 
transmission of the human immunodeficiency virus  to the infants (Zorilla et al., 2000; 
Merriam et al., 2003, Peltier et al., 2009).   
 
1.1 PROBLEM STATEMENT 
A group of women attending research clinics in Botswana initiated combination ARV 
treatment (HAART) during pregnancy as per Botswana treatment guidelines and for the 
purpose of prevention of mother to child transmission from the antenatal until the breast 
feeding period, and will continue with ARV treatment indefinitely for their own health. 
HAART is known to be more effective for the purpose of vertical transmission 
prevention compared to single or dual therapy (Thomas et al., 2008). HAART also 
decreases the morbidity and mortality of the women resulting in a further increased 
survival of the infants as well (Thomas et al., 2008). However high levels of adherence 
are required to achieve maximal viral suppression required for effective prevention of 
transmission to infants, and for prevention of development of resistance to available 
antiretroviral drugs. We do not know the current level of adherence to HAART among 
these pregnant and breastfeeding women and we do not know which factors impact either 
negatively or positively upon their adherence levels. 
 
1.2 PURPOSE 
The purpose of the study was to determine the level of adherence among the women 
described above and the factors associated with adherence. The information obtained was 
intended to be used to devise strategies to improve ARV adherence amongst the women 
at these clinics (if improvement was required) as well as  in other sites involved in the 
ARV rollout in Botswana, and potentially elsewhere, especially in developing countries. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.0 Introduction 
This section reviews literature relevant to the study. The review covers the following 
areas; overview and significance of adherence to ART amongst HIV/AIDS patients; 
known levels of adherence to antiretroviral drugs; factors that affect adherence; women 
and adherence; adherence among pregnant women and measurement of adherence.  
2.1 Overview and significance of adherence to ART amongst HIV/AIDS patients 
 
Dramatic reductions in HIV/AIDS related morbidity and mortality has been realised in 
most countries where Highly Active Antiretroviral Therapy (HAART) is widely available 
(Anderson & Weatherburn, 1999).  
 
HAART improves the life of HIV positive patients’ through control of disease 
progression by viral suppression and decreased transmission of resistant viruses, 
decreased incidence of opportunistic infections and decreased time spent away from work 
due to illness or associated hospitalisations (Turner, 2002). Unfortunately the level of 
adherence required for keeping good control of viral replication and reducing AIDS 
related mortality and morbidity required to sustain these benefits, is extremely high. 
Adherence rates of 95% or more are required for maximal viral suppression (Paterson et 
al., 2000). This level of adherence required for excellent adherence is supported by a 
study conducted within the REACH cohort in the US (Bangsberg, 2006). Bangsberg 
further concludes that lower levels of adherence (≥70%) would be adequate for 
maintaining viral suppression especially if the patient is receiving very potent non-
nucloeside reverse transcriptase inhibitor based therapy. Lack of adherence to 
medications is a major challenge to care, as this may lead to an increase in viral 
replication, development of viral mutations with consequent resistance to the few 
available drugs. This can result in treatment failure, increased incidence of opportunistic 
infections and shortened survival (Paterson et al., 2000).  
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Among pregnant women receiving HAART, sub optimal adherence will lead to increased 
risk of mother to child transmission of HIV during pregnancy, delivery and breastfeeding 
(Vaz et al., 2007). When compared to their non pregnant counterparts, Vaz and co-
workers in Sao Paulo, Brazil, found a significantly higher adherence among pregnant 
women. Forty three percent of the pregnant women had optimal adherence as measured 
via pill counts. This figure although low was much higher than the 17% optimal 
adherence recorded by their non pregnant counterparts. Among the same group of 
pregnant women, adherence decreased to 21% in the postnatal period. However, the 
factors that motivated higher adherence among the pregnant women were not evaluated. 
 
Vahove, Shapiro & Winters (1996), performed a careful analysis of viral load, number of 
doses of medications taken per day and the development of resistance among six HIV 
infected individuals, followed over a period of 24 weeks. They reported a decrease in 
viral load initially as all the participants were adherent; however, subsequent drug 
holidays lead to viral rebounds. This data suggests that poor adherence even within short 
periods may be associated with increased viral loads. However the small sample size 
limits the generalisability of this finding to other populations. 
 
From a public health perspective, poor adherence to HAART may result in transmission 
of resistant strains of the human immunodefficiencyvirus to newly infected individuals 
(primary resistance). This has a negative impact on their future response to antiretroviral 
therapy (Poppa et al., 2003). If resistance or treatment failure happens, current treatment 
guidelines recommends switching to a new HAART combination regimen, which may 
include more agents and more complex regimens, which in turn may be associated with 
new or unknown toxicity (Poppa et. al, 2003). Thus the health outcomes for individuals 
in this category are unpredictable and often poorer than those on first line therapy. 
 
The socio economic consequences of poor adherence are enormous as it will result in 
increased use of second-line and salvage regimens, which are in general more expensive 
than initial regimens. More so, since low adherence is associated with an increased risk of  
disease progression, the cost of hospitalisation and treatment of opportunistic infections 
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will have a negative impact on the established cost-benefit of antiretroviral therapy (Sherr 
et al, 2007). 
 
Poor adherence ultimately leads to severe public health consequences, namely; increased 
vertical and horizontal spread of the disease, increased cost of management, decreased 
human capital, increased social costs including care for orphans and decreased survival of 
children of those who are ill or dead as a result of inadequate care (Sherr et al, 2007).   
2.2 Levels of adherence to antiretroviral drugs 
Estimates of average adherence rates to HAART i.e. the use of these drugs at the right 
dose, frequency and at the agreed times range from 50-70% in many different social and 
cultural settings (Safren, 2005).  
 
Studies in African settings have indicated adherence rates as varying from 54%-98% 
depending on the method used to assess adherence. Nwokike (2004) reported 83% 
adherence in the public sector in Botswana amongst adult males and females as measured 
by patients self report and pill count while Weiser et al, (2003) reported 54% amongst 
adults in the private sector using patients self report only. 
 
Other findings by different researchers are; in Nigeria, 79% measured by patients self 
report amongst adults receiving care in a tertiary health care centre (Daniel, 2004); in 
South Africa, 77% amongst adults in the public sector measured by patients self report 
(Ferris, 2004) and in Uganda, 98% amongst adults in the public sector with measurement 
by patients self report (Munganzi, 2004). These data may not be comparable as the 
researchers used different methods in different settings; however it does show that the 
level of adherence varies amongst African countries.  
 
Concerns about low adherence has been cited by those who question the feasibility of 
rapidly scaling up antiretroviral therapy programmes especially in resource poor settings 
(Stephens, Kaye & Corrah, 2004). Harris, (2001) argued that adherence problems would 
continue to be a major concern to the delivery of antiretroviral therapy in Sub-Saharan 
Africa. This is understandable as high levels of poverty, poor health infrastructures, poor 
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social security system, illiteracy and unfamiliarity with the need for long term treatment 
especially when feeling well, are all factors which impact upon adherence and are all 
factors prevalent in Sub-Saharan Africa (WHO, 2006).  
 
However despite this truism it is worth noting that except for the study amongst private 
sector patients in Botswana by Weiser et al, (2003), all the studies listed above have 
reported acceptable levels of adherence.  It is also interesting that Nwokike (2004) found 
higher adherence levels amongst the Botswana public sector patients compared to lower 
levels reported by Weiser et al, (2003) in the private sector. This is counterintuitive since 
the adherence inhibiting factors listed above, which are commonly cited by policy 
makers, are much more prevalent amongst public sector patients. It is therefore quite 
important to review the factors affecting adherence (both promoters and inhibitors) in 
more detail and to assess how they might interact with one another.    
2.3 Factors affecting adherence 
Multiple factors are known to affect adherence to antiretroviral therapy, these are often 
classified into five interwoven categories (Reiter, 2000). They include: patient variables, 
treatment regimens, disease characteristics, clinic setting and the patient provider 
relationship. 
 
2.3.1 Patient variables 
These include socio-demographic factors such as age, sex, race, income, education, 
literacy, housing status, HIV risk factors and psychosocial factors i.e. mental health, 
substance abuse, socio-cultural issues, psychosocial support and knowledge about and 
attitude towards HIV and its treatment (Carrieri, Caillefon & Le moing, 2002). 
 
Patients who have a good understanding of the need to adhere to ARV’s and the 
consequences of treatment failure tend to adhere more than those without this information 
(Weiser et. al, 2003). Bangsberg and co-workers reported that 13% of patients who were 
prescribed ARV’s were not taking them correctly, despite them believing that they were 
(Bangsberg, Perry & Charlesbois, 2001). Reinforcing information provided verbally with 
written information to take home, and by checking that information delivered has been 
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heard correctly, is likely to be beneficial in improving adherence as patients commonly 
misunderstand their health care provider’s instructions (Kgatlwana et al., 2006).  
 
Socio-demographic, cultural and psychological issues have great potential to impact on 
adherence. Family support i.e. having to care for sick relatives and religious beliefs 
around illness and taking of medications may influence motivation and adherence 
(Klitzmann, 2004). This is starkly demonstrated by low levels of adherence amongst 
people who believe in divine healing (Powell-Cope, White, Henkelman & Turner, 2003). 
Individuals with unstable housing, i.e. not having one’s own house and the need to live 
with different relatives/friends at different times, inevitably have compromised privacy 
which consequently negatively impacts on adherence (Kgatlwane et al., 2006). The issue 
of disclosure has also been found to have serious implications for adherence; for 
example, the use of medication may inadvertently reveal a person’s HIV status and 
therefore patients may be reluctant to collect their medications, to store it in common 
storage space such as a medicine cupboard in the home and to take it in a common area 
such as a kitchen (Stirratt, Remien, Smith, Copeland, Dolezal & Krieger, 2006). This 
need to keep the medication a secret in order to protect the privacy of their HIV status 
compromises adherence.  
 
Poverty may prevent individuals from following treatment related dietary advice (Hardon 
et. al, 2007), and lack of food at prescribed dosage intervals would result in patients 
being unable to take some doses of their medication such as Atazanavir which should be 
taken with food. Transport costs to and from health facilities for medication appointments 
may have a negative influence on an individual’s ability to attend clinic appointments and 
hence to keep to their medication regimens (Kgatlwane et al., 2006).   
 
Drug and alcohol abuse may impair judgment and the ability to adopt and maintain 
routine medication use (Klitzmann, 2004). Also family responsibilities, such as, having to 
work to generate income for the family and provide care for sicker family members may 
require adults to place the health care needs of others before their own (Klitzmann, 2004), 
thus having a negative impact on their adherence to their medication. Mental health 
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problems such as depression have been associated with low adherence in HIV positive 
adults and adolescents, as have other psychological variables such as perception of one’s 
ability to follow a medication regimen (Murphy, 2004). 
 
2.3.2 Treatment regimens 
These include the number of pills prescribed, the complexity of the regimen (dosing 
frequency, food instructions and the specific type of ARV). Antiretroviral medications 
are usually taken once or twice daily at approximately specified times and some may 
require food restrictions like didanosine which is usually taken on an empty stomach i.e 
about 30 minutes before or 2 hours after meals ((Marfatia & Makrandi, 2005). These are 
obviously difficult to adhere to in our busy daily lives. Most available antiretroviral drugs 
have unpalatable side effects such as nausea, vomiting, diarrhoea, hepatotoxity and skin 
rashes, which have a negative impact on adherence levels. Thus as different regimens 
have different incidence, type and severity of side effects; they will have different levels 
of adherence (Carr, 2002). Machtinger & Bangsberg reported that increased pill burden 
associated with concurrent medication for other co-morbidities such as tuberculosis is 
clearly associated with sub-optimal adherence (Machtinger & Bangsberg, 2005). 
 
2.3.3 Disease characteristics 
Disease characteristics would include the stage and duration of HIV infection, associated 
opportunistic infections, and HIV related symptoms (Machtinger & Bangsberg, 2005). 
The severity of the illness could impact negatively or positively on adherence to ART. 
HIV infection has a long latent phase of about 8 to 10 years. Aside from a flu-like illness 
during the acute seroconversion period, infected individuals are usually asymptomatic 
during the latency phase. Following the latency period, there is the phase of full blown 
AIDS, consisting of rapidly increasing viral replication, declining cd4 counts and 
increasing frequency of opportunistic infections such as tuberculosis, papular pleuritic 
eruptions, weight loss and finally death in the absence of treatment (Weiser et al., 2003). 
With the use of and good adherence to anti-retroviral drugs most of these opportunistic 
infections are usually brought under control and individuals can lead a normal, healthy 
life.  
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Experience of symptoms and their impact on patients’ views about medications are 
usually complex (Carr, 2002). Symptoms may stimulate the use of medications by acting 
as a reminder or reinforcing beliefs about the necessity for treatment. However, patients’ 
expectations of symptom relief are also likely to have an important effect. This could be 
problematic for adherence if expectations are unrealistic, or where treatment is given for 
asymptomatic disease, as occurs with HIV infection (Horne, 2001). 
 
The desire to get well may make an individual comply with medications as prescribed. 
However with improved health, adherence to the medication becomes a problem as some 
may not understand why they have to continue taking the medications regularly, while 
they are healthy (Weiser et al., 2003). This results in poor adherence with consequent 
viral rebound, increased probability of resistance developing and consequent treatment 
failure. 
 
2.3.4 Clinic setting 
Chesney, (2000) found that dissatisfaction with the health services is a predictor of non 
adherence. Factors such as the ease of accessibility of a clinic i.e. if it is on a public 
transport route, general clinic environment i.e friendliness of staff, short waiting time, 
access to continuing primary health care and child care at the same clinic, would all lead 
to improved adherence (Machtinger & Bangsberg, 2005). Other factors includes flexible 
opening hours and convenient appointment scheduling tailored to individual patients 
needs i.e. work, holidays and travel; ability of health care staff to address patients 
concerns and willingness to help when needed, as well as perceived confidentiality of the 
care and setting; involvement in a dedicated adherence counselling  program; 
pleasantness of the clinic environment and satisfaction with past experience with the 
health care system, would all also lead to improved adherence (Hardon et. al, 2007). 
Long waiting time, poor drug supply chain with associated occasional stock-outs as well 
as absence of established HIV treatment guidelines were associated with sub-optimal 
adherence among patients on treatment in the study by Hardon cited above. Kgatlwane et 
al. (2006), in a Botswana study reported that poorly trained personnel, poor staff 
motivation and poor salaries lead to inadequate counseling and inadequate follow-up of 
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patients with consequent poor adherence. 
 
2.3.5 Patient provider relationship 
The patient provider relationship includes the patient’s overall satisfaction and trust in the 
particular provider; the patient’s opinion of the provider’s competence; the provider’s 
willingness to include the patient in the decision making process; the affective tone of the 
relationship (e.g. warmth, openness, cooperation); the compatibility of class, race, culture 
and language between patient and provider; and the adequacy of referral (Friendenberg, 
2006). All these affect adherence to HAART. With an increasing number of patients to 
care for on a daily basis, in a busy outpatient clinic in the era of HIV/AIDS, less and less 
time is being spent by physicians with patients, despite long waiting times for patients 
(WHO, 2006). Patients may therefore not have the opportunity to discuss concerns 
affecting their treatment with their physicians. Consequently with time trust diminishes 
and patients may find it difficult to adhere to their doctors instructions. 
2.4 Women and Adherence  
Little is presently known about the difference, if any, in treating women compared to men 
with regard to medication dosing and side effects. Likewise, few studies have explored 
what factors motivate women to adhere to HAART. Lake et al. (2003), found that 
connectedness with healthcare providers, especially female providers, as well as being 
attended to by nurses and nurse practitioners experienced in HIV/AIDS care, were 
important for women and lead to reports of better adherence. Sankar, Lubrosky, 
Schumann and Roberts (2002), found among African American women taking 
antiretroviral drugs that sources of motivation to adhere to drugs included; a positive 
relationship with their physician, belief that the drugs work, religiosity and faith in God, 
support from family members and the belief in the power of positive thinking. This study 
found an adherence rate of 69% among the women.  
 
Powell-Cope, White, Henkelman & Turner (2003), conducted a qualitative and 
quantitative assessment of ART adherence among 24 substance abusing HIV positive 
women. Their findings demonstrated that these women recognised the link between 
treatment benefits and adherence and most of them tracked viral loads and CD4 counts as 
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tangible evidence of effectiveness of treatment. Increased life span resulting in being able 
to spend more time with people familiarly and socially close to them such as children, a 
significant partner, friends and family, were expressed as advantages of adhering to ART. 
They also admitted that substance use was a difficult barrier to taking medication and 
they preferentially tended to stop ART rather than illegal drugs and alcohol. The use of 
reminders such as pill boxes, spirituality, adherence partners and support from family 
members promoted adherence among the cohort. The most common reason for missing 
medication was forgetfulness due to various circumstances. However, this study was 
conducted amongst a specific group of women in an urban setting with a small sample 
size which limited its generalisability to other populations. 
 
2.5 Pregnant Women and Adherence  
HAART has revolutionized Prevention of Mother to Child transmission programmes in 
the developed world compared to mono or dual therapy, with overall intrauterine and 
intrapartum transmission rates of less than 1 - 2% in non breastfeeding populations 
(Cooper et al. 2000; Dorenbaum et al., 2002; Thorne, 2005; WHO, 2007; Townsend et 
al., 2008; Warszawski et al., 2008). Emerging data from Sub-Saharan African countries 
suggest higher benefits of decreased HIV transmission and improved infant survival 
compared to single or dual therapy in the postnatal period among breastfeeding 
populations (Arendt et al., 2007; Shapiro et al., 2009).  
 
Successful interventions to prevent antenatal and intrapartum mother to child HIV 
transmission includes adherence to HAART medication and caesarean section mode of 
delivery (Kingston et al., 2007) Low adherence has been identified as the single most 
important challenge to preventing vertical HIV transmission with the use of HAART 
(Weigberg et al., 2009), current knowledge of adherence during pregnancy is limited. 
Poor adherence to ARVs during pregnancy can lead to suboptimal viral suppression, 
development of viral resistance, a higher risk of mother to child transmission (MTCT), 
and mother to child transmission of a resistant HIV-1 strain (Wells et al., 2000; Johnson 
et al., 2001). 
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While some studies have indicated that adherence is much higher during pregnancy than 
postpartum (Zorilla et al., 2003; Park, Tochuku and Grigoriu, 2007, Vaz et al., 2007), 
others have found high rates of non-adherence during pregnancy, particularly when more 
objective measures of adherence, such as pharmacy data or urine assays, are used (Demas 
et al., 2005; Laine et al., 2000). These findings may suggest that pregnant women are 
more likely to report higher adherence than they actually have. 
 
Cotter, Gonzalez, Duthely & O’Sullivan (2004) using a hospital database of HIV positive 
pregnant women on antiretroviral therapy found a perinatal HIV transmission rate of 
4.5%. Among the women who transmitted the virus, 41% were not adherent to their 
prescribed ARV medications (ie taking the medications at >95% of times), thus echoing 
the importance of adherence to HAART among pregnant women. However adherence 
among women who did not transmit the virus to their babies was not reported by the 
authors. 
 
In a Brazilian study among pregnant and non pregnant women with comparable 
demographic characteristics, using pill counts and self reporting, 43.1% of pregnant 
women achieved adherence rates of ≥95% (Vaz et al., 2007). This was significantly 
higher than non pregnant women where only 17.1% achieved ≥95% adherence. Although 
being pregnant was clearly strongly associated with higher levels of adherence the 
underlying motivating factors for this higher adherence were not formally assessed. It 
was surmised that fear of transmitting the virus to the foetus would have led to a better 
adherence among the pregnant women, although this was not measured in this study. It is 
also possible that increased expectation by the health care workers that they are taking the 
medication regularly, as it would prevent their child from getting infected with HIV, 
might result in increased reporting of higher adherence by pregnant women. This was 
also not assessed in the study above.  
 
The dominant risk factor for MTCT is high maternal viral load at delivery (Thorne et al., 
2005; Jourdain et al., 2007; Warszawski et al., 2008) which is a function of sub-optimal 
adherence. Optimal adherence during pregnancy and delivery is necessary to ensure 
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adequate immunologic and virologic responses (Weinberg et al., 2009; Melekhin et al., 
2009). In a study amongst pregnant women in the United states of America, Bardeguez et 
al. (2008) found that pregnant woman with perfect adherence (100% by self report) had 
lower viral loads. Out of a total of 519 eligible subjects, 75% reported perfect adherence 
during pregnancy. The odds of perfect adherence were significantly higher for women 
who initiated ARVs during pregnancy, did not have AIDS, never missed prenatal 
vitamins, never used illicit drugs and had generally good social relationships.  
 
A complex set of factors likely influences adherence among HIV-infected pregnant or 
postpartum women. In other populations, pregnancy has been a significant motivator for 
reducing aberrant health behaviours (e.g. smoking and alcohol use) and women with 
chronic health conditions (e.g. diabetes) may improve adherence during pregnancy, but 
then revert to poor health behaviours postpartum (Zorilla et al., 2003).  
 
Although better ART adherence during pregnancy compared to postpartum have been 
shown in several studies as described above in this section, high rates of non-adherence 
have also been shown in both groups. Ickovics et al., (2002) reported that only 50% and 
34.1% of United States women studied adhered to their medications in the antenatal and 
postnatal periods respectively.     
 
These analyses indicate that medication adherence is more likely during pregnancy than 
postpartum in HIV-infected women, perhaps provoked by the motivation to reduce 
vertical transmission, intensive antepartum encouragement and surveillance, or a 
combination of both.  
2.6 Measurement of Adherence 
Measurement of adherence is imperfect and lacks an established gold standard (Gill, 
2005). Many studies employ various methods, either alone or in combination to measure 
adherence. Methods used includes medication event monitoring (MEM) cap technology 
which involves the use of smart pill bottles that contain computer chips which 
electronically measures every opening of the bottle (Vitolins, 2000). This is a complex 
and expensive method and may only be useful in research rather than in clinical settings. 
 
 
 
 
 17
It could also be very unreliable, especially in developing countries, as patients may open 
the pill bottle without actually taking out pills or swallowing them. However this would 
constitute deliberate, premeditated and regularly carried out duping of the health worker, 
whcih is unlikely to occur unless there is a serious disagreement between the patient and 
the health worker on the usefulness of the medication. Other methods that have been used 
by researchers in developing country settings includes: pill counts, patients self reported 
adherence, biochemical markers, pharmacy prescription refill records and modified 
directly observed therapy (Gill, 2005). 
 
Pill count adherence is usually measured by counting the pills the patient returns at each 
medication refill visit (Machtinger & Bangsberg, 2005). The method assumes that 
remaining pills in excess of what is expected represents missed doses. It can be 
performed in the clinic or at unannounced home visits. It is quick and easy to do, 
although validity of the method might be compromised as the patients may take out the 
pills which they should have taken, even if they haven’t taken them, and hence this 
method may overestimate adherence. It could also underestimate adherence if at the 
previous dispensing the patient was inadvertently given more medication than required, 
or if the patient has accumulated a stock of previously unused medication and hence did 
not have to use all the medication received at the last dispensing in order to be fully 
adherent.    
 
Patient self reported adherence is done in the clinic setting by asking the patient to recall 
any missed doses at specified time points in the past, for example 1-day recall, 3-day 
recall and 7-day recall (Machtinger & Bangsberg, 2005). It is simple, efficient and easy 
to perform, however it is a less sensitive measure of adherence as patients may tell the 
health worker what they want to hear and hence it often overestimates adherence. This 
method is unlikely to underestimate adherence. The method is most valid and hence most 
useful when there is a high degree of trust between the patient and the 
clinician/pharmacist.   
 
Biochemical markers of adherence refer to measurements of the concentration of the 
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antiretroviral drugs in the plasma (Machtinger & Bangsberg, 2005). Plasma 
concentrations of some studied antiretroviral drugs have been correlated with adherence 
and viral load levels. The lower the drug level in the plasma, the less likely it is that the 
patient is optimally adhering. However this method is limited by its ability to measure 
only short term adherence behaviour and also drug levels may be affected by several 
other factors such as individual metabolic differences, poor absorption and inter-drug 
interaction. Hence it can overestimate and underestimate adherence levels.  
 
Pharmacy prescription refill records can be used to assess adherence by recording the 
dates antiretroviral medications were dispensed to patients (Machtinger & Bangsberg, 
2005). If refills are not obtained at the expected dates, it assumes that (1) the patient is 
completely non-adherent from the missed refill date since s/he has no medication to take; 
or (2) that the patient has been partially adherent since the last refill period and hence has 
excess pills remaining beyond the scheduled refill date, which s/he is now taking and 
hence has not appeared timeously for the next refill; or (3) the patient may have obtained 
a medication refill at a different health facility or pharmacy and adherence levels is then 
impossible to assess. It is therefore a poor measure of adherence and at best can be used 
to assess if adherence levels are very low, or complete non-adherence provided that the 
patient has only one or very limited places where medication refills can be issued.    
 
Modified directly observed therapy (MDOT) adherence assessment is used when a health 
worker observes most but not all of the medication at the time the patient is taking them 
(Machtinger & Bangsberg, 2005). An example is where a health worker observes the 
patient taking the morning dose and pre packages the evening dose for the patient to take 
at home. It is useful in patients with severe difficulty adhering and also in ambulatory 
settings. It is an accurate and valid adherence measurement; however, it is cumbersome 
and labour intensive to implement. A full directly observed therapy (DOT) could 
similarly be used to assess adherence, but it is clearly even more cumbersome and labour 
intensive than MDOT.  
 
Therefore, no single measure of adherence is appropriate for all settings or outcomes. As 
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adherence is a dynamic process, it is believed that the use of more than one measure 
might allow the strength of one method to compensate for the weakness of the other and 
to capture more accurately the information needed to determine adherence levels 
(Vitolins, 2000). In the absence of a practical gold standard, measurement of adherence is 
usually done by the most feasible method for the circumstances, while noting the 
deficiencies of the measurement method chosen. Table 2.1 below summarises the 
strengths and weaknesses of some of the methods used to determine adherence.  
 
Table 2.1: Strengths and Weaknesses of different adherence measures. 
Method Strengths Weaknesses 
MEMS cap 
technology 
Accurate It is expensive; patients may open the bottle without taking 
out or swallowing the pills. This would be deliberate, 
premeditated and regularly carried out if doubting the health 
worker. However, this is unlikely to occur unless there is a 
serious disagreement between the patient and the health 
worker on the use of the medication. 
Measurements of 
drug levels 
Very accurate in 
determining the level 
of a particular drug in 
blood or urine. 
Invasive, expensive. 
Measures short term adherence. 
Pill count Easy to perform, quick Patient may return only those pills which would be left over 
if they had high (100%) levels of adherence rather than all 
the pills that are left over. 
Pharmacy refill Accurate in measuring 
very low adherence 
Requires a lot of documentation; patients may collect 
medication elsewhere; coarse measurement of adherence as it 
measures when adherence is very low (0% or close to 0%); 
cannot be used to assess degree of adherence in terms of 
number of pills taken at appropriate times of the day. 
Patient self report Builds trust and 
confidence, easy to do. 
Patient may want to please the health workers, thus they 
could give incorrect information; gives an over estimate of 
adherence. 
 
CHAPTER 3 
AIM AND OBJECTIVES 
 
This chapter describes the aims and objectives of the study. 
3.1 Aim 
• To assess the level of adherence and to identify the barriers to adherence and 
motivation for good adherence to antiretroviral therapy amongst women who 
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commenced treatment while pregnant at research clinics in Molepolole, Mochudi, 
Lobatse and Gaborone. 
 
3.2 Objectives 
• To determine the proportion of women who are adequately adhering to their ART. 
• To compare the socioeconomic, demographic, religious and cultural 
characteristics of the women who are adequately adhering and those who are not. 
• To compare the knowledge and attitudes towards ARV’s between the women who 
are adequately adhering and those who are not. 
• To compare the access to and the level of satisfaction with health care services as 
perceived by the patients and its association with adherence. 
• To compare patient’s adherence with disease severity as measured by viral load, 
CD4 counts and presence of complications. 
• To assess the association between side effects and adherence. 
• To assess the association between the level of counselling and adherence. 
• To assess the adherence levels in the antenatal, early postnatal (≤ 6 months) and 
late postnatal (≥ 6 months postpartum) periods. 
 
 
 
 
 
 
                                                            CHAPTER 4 
METHODOLOGY 
 
4.0 Introduction 
This section describes the study design, study population, sampling, data collection tools 
and methods, data analysis, validity and reliability of the study, as well as ethical 
considerations.    
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4.1 Study Design 
A quantitative study was conducted using a cross-sectional descriptive design. This 
design enables the identification of the characteristics of the women who are adhering to 
their medications and those who are not, establishes the magnitude of the problem, as 
well as compares their characteristics. It was therefore possible to quantify the current 
levels of adherence to HAART at the research clinics and explore potential factors 
associated with the identified levels of adherence. 
4.2 Study Population 
The study population consisted of all women who enrolled in the observational arm of the 
ongoing clinical trial, who initiated antiretroviral treatment at the research clinics in 
Molepolole, Lobatse, Mochudi and Gaborone in Botswana and who were still being 
followed-up during the study period. They were being followed-up for 2years after 
delivery and at the time of data collection, only 100 of the women were still being 
followed-up. Those who had left the study and were no longer being actively followed-up 
were not included in the study population as the logistical difficulties in tracing them 
would be considerable (they were receiving treatment at a diverse array of public and 
private facilities after they completed their 2 year follow-up), resulting in an inevitable 
low sample realisation level. The study was therefore restricted to those women who had 
not yet reached 2 years on treatment with the consequence that only short and medium 
term adherence could be assessed, as all the participants on long term treatment (> 2 
years) were then excluded.   
4.3 Sampling 
This was not necessary because of the small sample size. All 100 women who enrolled in 
the observational arm of the study and were still within the 2-year active follow up period 
were requested to participate in the study.  
4.4 Data Collection Methods 
 
During their routine monthly HAART medication refill visits over a period of 
approximately six weeks, (this time was sufficient to access all prospective participants 
as the women attended the clinic monthly) participants were approached and the study 
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was introduced to them. Informed consent was then obtained from those interested in 
participating in the study. Following the informed consent process, the structured 
questionnaire was administered by a trained research assistant who understands the local 
language very well. Additional data were extracted from the patient’s medical records 
using a structured data collection tool. The research assistant was trained in the study 
procedures and human subjects’ research ethics. She also had extensive previous 
experience in conducting health research interviews and administering of questionnaires 
to research subjects.   
 
The interviewer administered structured questionnaire had both open and closed ended 
questions. Participant specific identifiers were used to ensure that no participant was 
interviewed more than once. Participants were interviewed in a quiet private room by the 
research assistant who was independent of the clinic staff and the larger research study. 
Enough time was taken to ensure that the participants understood the questions before 
answering them. The questionnaire captured information on their self reported adherence 
levels, their socio demographic indices as well as their knowledge and perceptions 
towards antiretroviral therapy and other factors that may influence their adherence to 
treatment, as listed in the objectives section. The questionnaire was based on the 
literature review on adherence and it is similar to what was used in the Kgatlwane et al. 
(2006) adherence study in Botswana (see Appendix 1).  
 
Records of their ARV regimens (and any changes since the start of their treatment), 
length on treatment, experience of side effects, pill counts, medication refill appointments 
missed in the past 6 months, current CD4 count and viral loads as well as disease stage 
was extracted from their clinical records (see Appendix 2). The research sites kept good 
records of pill counts at each medication refill visit and maintained a good diary of 
medication refill appointments attended or missed.   
 
4.5 Data Analysis 
Data was coded and captured electronically. Accurate coding was ensured by entering the 
questionnaire data into epi info and double keying at least 10% of the questionnaires 
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using the epi info data entry module. Data was then cleaned and exported to SPSS 
version 14 for analysis. Medium term adherence rates measured via pill counts for the 
past 6 months was defined as the number of doses taken divided by the number of doses 
prescribed. Due to the high levels of adherence noted among the study population, 
subjects were categorized as excellent adherence (taking 100% of pills), adequate 
adherence (taking >=95% of pills) and inadequate adherence (taking < 95% of pills).    
 
Medication refill appointment records are a coarse measure of adherence, all participants 
were given one month’s supply of medication at a time and therefore had to collect their 
medication refills every month. Missing one medication refill appointment within the last 
6 months was categorised as inadequate adherence. Participants who attended all six 
medication refill appointments during the last six months were categorised as adequate 
adherence.  
 
The adherence level by self report (1 day, 3 days and 7 days recall) was analysed to 
assess short term adherence level. Descriptive statistics was used to assess socio 
economic and demographic characteristics of the women, as well as other variables. 
Bivariate analysis comparing potential causative factors with dichotomous cut-off 
adherence levels was used to examine the potential factors affecting the different 
measures of adherence. The Chi-square test for independence was used to test the 
association between the various variables and the dichotomised adherence levels.  
Knowledge of HIV/AIDS and ARV’s was measured using a 5-point Likert scale to 
determine the degree of participants’ responses, where ‘strongly disagree’ scored 1, 
‘disagree’ scored 2, ‘agree’ scored 3 and ‘strongly agree’ scored 4. Participants who were 
unable to choose from 1 to 4 were scored 5 (uncertain).  The composite variable, 
knowledge was constructed using 13 knowledge questions. Those who responded 
correctly to 75% of the questions were rated as having high knowledge, 50 – 74% 
average knowledge and < 50% as poor knowledge. Scores of 3 and 4 (agree and strongly 
agree) to positive questions were graded as correct, while scores of 1 and 2 (strongly 
disagree and disagree) to negative questions were also graded as correct responses.   
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Level of satisfaction with the health care system was assessed using standardised 
questions (Kgatlwane et al., 2006). Length of time on treatment was categorised as ≥6 
months to <12 months, ≥12 months to <18 months and  ≥18 months to <24 months. 
Participant’s current viral load data (categorised as <50 or ≥50) and CD4 data 
(categorised as < 200 or ≥200) were analysed descriptively.  Disease severity was 
assessed using the WHO staging criteria for HIV/AIDS (see appendix 3). Data was 
analysed descriptively and then cross tabulated with adherence levels via bivariate 
analysis with the associated chi square test for independence reported as well.  
 
Experience of side effects was measured via any record of any adverse event in the 
participants’ folders during the last 6 months. Level of counselling received was defined 
as ‘adequate’ when the participants reported that they found the counselling sessions very 
useful or useful and ‘inadequate’ when the participants reported that they found the 
counselling sessions not useful or only slightly useful.  
4.6  Piloting of the Data collection tools 
The questionnaire and records review tools were piloted using 5 participants (and their 
folders) who were part of the final sample to check for clarity of questions, time and 
consistency and ease of use by the research assistant. This process helped to slightly 
modify the instruments and ensured that the data collection tools were adequate in design 
and user friendly.  
4.7 Validity 
There is no gold standard for measuring adherence. Self reported adherence is likely to 
result in an overestimation of adherence as participants may attempt to please the 
interviewer and recall bias may also affect the accuracy of self reporting. Pill counts are 
based on the fact that participants took the pills which they did not return and did not 
discard or retain any of them.  There may also be measurement errors associated with pill 
counts leading to overestimation or underestimation of adherence. If a participant 
discards (or retains) the pills they were supposed to take and returns the exactly correct 
residual by deduction, it then would appear that the participant was 100% adherent 
leading to an overestimation of adherence. Underestimation or overestimation of 
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adherence may occur if the remaining returned pills were not counted correctly.   
 
The estimates of adherence from pill count data were intended to be combined with the 
self reported levels of adherence in an attempt to improve the validity of the 
measurements, as the strengths of one measurement will compensate for the weaknesses 
of the other. All women in the observational arm of the main study who were still being 
followed up and consented to participation in the study were interviewed, this minimised 
the possibility of selection bias. . Pharmacy refill adherence may be underestimated if the 
patient obtains drug from elsewhere and overestimated if patient got a refill but did not 
eventually swallow the pills. 
 
The interviews were conducted by a trained research assistant who was neither part of the 
main project research team nor a staff member at the clinics, thus minimising the 
possibility of participants overrating access to services and counselling received at the 
clinic and overestimating adherence levels. The questionnaire was developed using an 
extensive literature review and a pre-existing questionnaire, and therefore it would at 
least have face validity. A strenuous attempt was made to use unambiguous questions and 
the research assistant was carefully trained to administer the questionnaire in a 
standardised manner. Data from the participants’ medical records were highly 
comprehensive and accurate, as the facilities are research clinics which are geared to 
collecting data. The research assistant was also trained to collect the data from the 
medical records in a standardised manner.    
 
4.8 Reliability 
Given the standardised data collection instruments and the standardised training, 
reliability is likely to be high, although reliability was not formally assessed. 
4.9 Ethical Considerations 
HIV/AIDS is a highly stigmatizing disease, thus the highest ethical conduct was 
necessary for this study. Ethical clearance was obtained from UWC ethics committee. 
Permission to conduct the research was obtained from the research site, the Principal 
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investigator of the larger project and the Botswana Health Research Development 
Committee (HRDC). Informed consent was obtained from the patients before the 
questionnaire was administered to them. Participants were allowed to refuse participation 
and their refusal had no effect on their treatment and care. Also they could withdraw at 
any stage of the study without giving any reason for their withdrawal and this would not 
affect their treatment or care at the clinic. Careful measures were taken to maintain 
participants’ confidentiality. Counselling was offered to those who were having problems 
with adhering to their medications.  
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CHAPTER 5 
RESULTS 
5.0 Introduction 
This chapter gives a summary of the results of the study in both descriptive and analytical 
form. A total of Ninety four (94) women out of the one hundred (100) women who were 
still being followed-up during the study period consented, and were interviewed.  Data 
were also extracted from their medical records. Out of the 6 women who were not 
interviewed, 5 did not consent, and 1 did not return for her pills during the recruitment 
period and could not be reached by telephone (probably moved out of the study area).  
In order to understand the factors affecting adherence, the analysis examined the 
characteristics of the study population, the socio-economic status of participants, access 
to health services, adequacy of counseling, knowledge and attitudes towards HIV/AIDS 
and antiretroviral treatment, disease and treatment characteristics in relation to adherence 
to ART. 
 
5.1 Demographic and socio economic information of study participants 
Table 5.1 gives a summary of the socio-demographic characteristics of the study 
participants. Most of the participants (55%) were in the age group 31 – 40 years. The 
lowest age for participation in this study was 21years because the larger project had an 
age criterion; i.e. women less than 21years were excluded as 21years was the cut-off age 
of consent in Botswana for research purposes at the time that the project commenced.   
 
The majority of the participants (68%) were single, and most of the participants were of 
Christian religious background (66%). There were no participants of Muslim and African 
traditional religion in this study, which is an unusual finding as both of these religions 
have a large minority presence in Botswana (CSO, 2001). It is possible that for some 
unknown reasons women in these groups did not enroll into the main study. “Other” 
might have been chosen in the questionnaire by those who believe in God but are not 
practicing any of the religions listed or chose not to disclose their religious affiliations.  
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A high level of education status was recorded, with 70% of the participants having 
received secondary education. This may reflect the fact that access to education has in the 
recent past been free in Botswana, with a minimal fee introduced in the past 2-3 years for 
some people and an ongoing government social support program for those living below 
the poverty line, or assessed to be exempted due to their socioeconomic status. However, 
there were no participants in this study with a tertiary level education despite tertiary 
education being government supported through a study grant and/or loan to all who 
qualify to be admitted to both public and private tertiary institutions (Botswana Ministry 
of Education and Skills Development, 2009). The lack of participants with tertiary 
education is probably because they are more likely to use private sector facilities which 
supply HAART during their pregnancy, rather than the research clinics or the public 
sector clinics.   
 
Table 5.1: Socio-demographic characteristics of the participants (n=94 for all the variables) 
Variable Number Percentage 
Age 
21 – 30 36 38
31 – 40 52 55
> 40 6 6
Marital status 
Single 64 68
Married 10 11
Cohabiting 20 21
Religion 
Christian 62 66
Atheism 5 5
Other 27 29
Education 
primary or less 28 30
Secondary 66 70
Employment status 
Employed 33 35
Unemployed 45 48
self-employed 16 17
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Table 5.2 gives a summary of the socio-economic characteristics of the participants. 
Formal employment was not high and a large majority of the participant’s income was 
less than Botswana Pula (BWP) 1500 per month (approximately 2000 rands or 300 
United States Dollars). Very few (5%) participants missed a dose of medication due to 
lack of food.  
 
 
Table 5.2: Socio-economic characteristics of the participants 
Variable Number Percentage
Income in Pula (n=49) 
< 500 13 27
501 – 1000 18 37
1001 – 1500 7 14
> 1500 11 22
No. in household (n=94) 
1 – 5 57 61
6 – 10 29 31
> 10 8 9
Ever missed dose due to lack of 
food (n=93) 
Yes 5 5
No 88 94
Electricity in compound(n=94) 
Yes 43 46
No 51 54
Toilet facility in compound (n=94) 
Yes 78 83
No 16 17
Type of toilet facility (n=94) 
Adequate (flush toilet/private pit 
latrine) 76 81
Inadequate (shared pit latrine with 
other compounds) 18 19
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5.2 Levels of Adherence 
5.2.1 Adherence by participant self report 
No missed doses were reported by participants in the 1 day recall, 3 day recall and 7 day 
recall. The adherence level was hence recorded as 100% for all participants for each of 
the recall periods.  
 
5.2.2 Adherence by Pill count 
Pill count adherence over 6 months was very high with 99% of the participants having 
95% adherence or higher. Using the “adequate” or “optimal” recommended adherence of 
95%, the results indicate a very high level of adherence in this cohort. However if 
adherence was examined using the absolute 100% target for “excellent” adherence, the 
pill count adherence level was 67% (Figure 5.1).  
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Figure 5.1: Distribution of the level of adherence of the participants as measured by pill 
count over a 6 months period (n=94) 
 
As self reported adherence was 100% for everyone (section 5.2.1), I did not combine the 
results of self reported adherence and pill count adherence as initially planned, as doing 
this will not improve the validity of the results. 
 
5.2.3 Adherence by Pill count stratified by pregnancy stage 
Very high adherence levels were recorded across the three pregnancy periods. Figure 5.2 
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below, shows the distribution of the participant’s adherence levels stratified by stages. 
 
Figure 5.2: Distribution of the levels of adherence by 6 months pill count (n=94), by 
antenatal, post delivery (up to 6months after delivery) and late postnatal periods (greater 
than 6 months after delivery). 
 
5.2.4 Adherence by missed medication refill appointment  
Table 5.3 shows the frequency distribution of the missed medication refill visits in the 
past 6 months stratified by pregnancy stage. There was a high adherence to medication 
refill appointments across the scheduled pharmacy refill visits throughout the three 
different pregnancy stages. The mean adherence to refill appointments was 97.9% and 
decreased very slightly from 98.9% in the antenatal period to 96.8% in the late postnatal 
period (see Table 5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32
Table 5.3: Missed medication refill appointment in the past 6months stratified by 
pregnancy stage. 
Missed 
medication 
Refill 
Appointment 
Antenatal period 
Immediate 
Postnatal period Late Postnatal Period Mean 
% 
No Percentage No Percentage No Percentage 
Yes 1 1.1 2 2.1 3 3.2 2.1 
No 93 98.9 92 97.9 91 96.8 97.9 
Total 94 100 94 100 94 100 100 
        
 
5.3 Univariate Analysis of potential factors associated with Adherence. 
5.3.1 Disclosure of HIV status 
The level of disclosure in this cohort was very high. Eighty eight (94%) of the 
participants had disclosed their status to at least 1 person.  Of the 6 participants who did 
not disclose their HIV status 5 were single and 1 was cohabiting. Figures 5.3 and 5.4 and 
shows disclosure stratified by marital status and who disclosed to. 
 
 Figure 5.3: Distribution of percent disclosure stratified by marital status of the 
participants. 
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Figure 5.4: Distribution of whom in the household the participant disclosed to (multiple 
responses allowed) n=64 for single and n=30 for married or cohabiting 
 
5.3.2 Access to Health services 
5.3.2.1 Time to clinic and mode of transport 
Figures 5.5 show the distribution of the time taken to travel to the clinic. Most of the 
participants took 30 minutes or less to travel to the clinic and 89% travelled for at most 1 
hour (Figure 5.5). Some participants (68%) noted that there is generally a loss of income 
related to time taken to visit the health facility and 17 (18%) reported an increase in 
expenditure. Out of those who reported an increase in expenditure, 12 (71%) attributed 
the increase to transport costs. 
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Figure 5.5: Distribution of the time taken to travel to the clinic 
 
 
5.3.3 Adequacy of Service and Level of Counseling 
 
Participants were asked to rate the frequency, adequacy and level of counseling they 
received at the health facility. Almost all the participants (99%) stated they were formally 
counseled before or when they started treatment, yet 30% stated that they have never 
again received formal adherence counseling after they started HAART (Figure 5.6).  
Almost all participants reported being satisfied with both the adequacy of the counseling 
(Figure 5.7) and the overall quality of the health services (Figure 5.8). 
 
 
Figure 5.6: Rating of the frequency of adherence counseling by the participants (n=93) 
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Figure 5.7: Rating of the adequacy of counseling by the participants (n=93) 
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Figure 5.8: Rating of the overall quality of the services offered at the health facility (n= 
93). 
 
Participants were asked if they talked to the health worker about their experience of using 
the medicines and if health workers enquired about and monitored their medication 
experiences. The results are shown in table 5.4. The overwhelmingly positive results 
indicate that this cohort received consistent adherence monitoring, via the pill count 
method.  
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Table 5.4: Continuing Adherence Monitoring 
 Adherence counseling Number Percent 
 Did you talk with the health worker about your experience 
of using your medicines?   
  Yes 88 94 
  No 6 6 
  Total 94 100 
Did the health worker ask you if you have missed a dose of 
your medication?   
  Yes 87 99 
  No 1 1 
  Total 88 100 
 Did the health worker explain to you what the effects of 
missing a dose are?   
  Yes 80 91 
  No 8 9 
  Total 88 100 
Did the health worker ask if you are taking other medicines 
or traditional medicines?   
 Yes 71 81 
 No 17 19 
 Total 88 100 
Did the health worker count your pills before giving you a 
new supply?   
 Yes 93 99 
 No 1 1 
 Total 94 100 
 
5.3.4 Knowledge of ARV’s and HIV/AIDS 
In order to evaluate the impact of knowledge of ARV adherence specifically and ARVs 
and HIV/AIDS in general, participants were asked a series of 13 knowledge questions. 
There was a high level of knowledge among the participants (Table 5.5a and Table 5.5b), 
reinforcing the previous findings about consistent adherence monitoring and informal 
counseling during the health facility visits. More than 90% responded correctly to most of 
the knowledge questions, that is either agree or strongly agree to positive statements 
about ARVs and HIV/AIDS or disagree/strongly disagree about negative statements 
about ARVs and HIV/AIDS.  Some participants were not very clear on the technical 
issues about what happens to the virus levels during treatment, as 87% responded 
correctly (Table 5.5a). Figure 5.9 ranks the high level of knowledge graphically for the 
percent of participants who responded correctly to the specified questions. When using 
the composite score (% of correct responses to knowledge questions), a total of 94.7% 
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achieved an excellent knowledge of greater than or equal to 75% of all questions 
correctly answered.   
 
Table 5.5a: Knowledge on ARV adherence  
Knowledge question: About ARVs  
“What happens if you stop taking your 
medications”                                           N = 94 
Response (%) 
disagree agree uncertain 
Your health will get worse? 1.1 96.8 2.1 
You may develop opportunistic infections 2.1 96.8 1.1 
Nothing will happen? 93.6 4.3 2.1 
Your CD4 will decrease? 3.2 95.7 1.1 
You may loose weight? 5.3 90.4 4.3 
You may develop diarrhoea? 6.4 76.6 17.0 
Your viral load will increase? 8.5 87.2 4.3 
 
 
 
Table 5.5b: Knowledge of HIV/AIDS and ARVs 
Knowledge question: About HIV/AIDS (N =94) 
 
Response (%) 
disagree agree uncertain 
Disease has no cure for now and therefore I need 
to continue treatment forever?  100.0  
Treatment helps to prolong life? 1.1 97.9 1.1 
Taking of ARV’s may result in experience of 
side effects like nausea, vomiting, hepatitis, low 
blood count and diarrhoea? 3.2 90.4 6.4 
Treatment helps to reduce the chances of 
transmission to the unborn and breast feeding 
infants? 2.1 97.9  
ARV’s work by suppressing viral load and 
increasing CD4 counts, do you agree?  1.1 98.9  
ARV’s can interact with other drugs including 
indigenous or traditional medications causing 
serious reaction?  5.3 90.4 4.3 
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Figure 5.9: Knowledge of the participants on effects of ART and HIV/AIDS (n=94) 
 
 
5.3.5 ARV regimens and duration on treatment 
 
Most of the patients (88.3%) were on AZT/3TC/Nevaripine (AZT/3TC/NVP), the 
recommended initial first line drug in Botswana which was used for this cohort in the 
parent study (table 4.6). Most of the participants (96%) were still receiving first line 
treatment indicating successful response to therapy. 
 
Table 5.6:  Participants ARV regimens and treatment type 
 Treatment Regimen Number Percent 
 Aluvia/Combivir  (ALU/CBV) 1 1.1
  Aluvia/Nevirapine (ALU/NVP) 1 1.1
  Aluvia/Truvada (ALU/TRU) 1 1.1
  AZT/3TC/Nevirapine 
(AZT/3TC/NVP) 83 88.3
  Nevirapine/Truvada (NVP/TRU) 8 8.5
  Total 94 100.0
 Regimen Type   
 First Line 90 95.7
  Second Line 4 4.3
  Total 94 100.0
 
 
 
 
 
 
 39
5.3.6 Reasons for Missing Medications 
Participants were asked if they have ever missed any medications because of some 
specified reasons. A total of 18% reported to have missed some medications due to 
forgetfulness, while 13% did not have the pills at the time they needed to take them. Very 
few participants missed their medication due to the number of pills to be taken, side 
effects or feeling better (Figure 4.10) 
2
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Figure 5.10: Reasons for ever missing medications (n=94) 
5.3.7 Disease characteristics 
Most (80%) of the participants in the study were WHO stage I/II disease. The CD4 
counts levels were lower in the antenatal stage and increased with time on treatment, 
however these increases were not statistically significant (Figure 5.11). Figure 5.11 also 
shows the distribution of CD4 counts by stage. The mean CD4 counts during the 
antenatal, immediate postnatal and late postnatal periods were 266, 316 and 346 
respectively. There was no association between the mean change in CD4 counts at the 
three time points: antenatal vs. immediate postnatal period (p = 0.458); antenatal vs. late 
postnatal period (p=659); and immediate postnatal vs. late postnatal period (p=0.714).  
 
The proportion of subjects with undetectable viral load increased sequentially from the 
antenatal period (82%), through the immediate post natal period (93%) and on to late post 
natal period (94%).  The participants had been on treatment on average for 20 months 
(Figure 5.12) however there was no evidence for any correlation between time on 
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treatment and adherence (spearman’s rho = 0.064; p = 0.539). 
                                                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Distribution of CD4 counts at different pregnancy stages. 
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Figure 5.12 below shows length of participants’ time on follow up in the parent study 
during the conduct of this study. 1(1.1%) has been on follow up for <1year while 
93(98.9%) has been on follow up for more than one year 
Figure 5.12: Distribution of participants’ time on treatment. 
 
5.4 Bivariate Analysis of Potential factors associated with Adherence 
As self reported short term adherence was 100% for all participants and missed 
medication refill levels were 97.9%, it was prudent to use the 6 months pill count 
measure of adherence in the bivariate analysis. In order to explore the potential 
association of various factors with adherence, the “perfect” adherence level (100% 
adherence) was used, because there were only 1% of the participants in the study that did 
not reach the “adequate” level of greater than or equal to 95% adherence by pill count.  
 
Table 5.8 shows a cross tabulation of various patient characteristics with “perfect” 
(100%) and “imperfect” <100% adherence by pill count. There was no significant finding 
when any of the factors were cross tabulated with “perfect” and “imperfect” adherence. , 
Since on bivariate analysis none of the potential predictors of adherence showed any 
significant association with adherence, multivariate analysis was not appropriate. 
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Table 5.8: Pill count Adherence and Patient characteristics                                                           
* Fishers exact test                    
 
 
Variable 
Imperfect 
Adherence  
(< 100%) 
Perfect 
Adherence 
(100%) 
Prevalence 
Ratio 
95% 
confidence 
Interval 
P value 
Age      
<= 30 13 23    
> 30 18 40 1.16 0.63 - 2.08 0.61 
Marital Status      
Single 21 43    
Married and cohabiting 10 20 0.98 0.53 - 1.82 0.55 
Religion      
Christian 20 42    
Other 11 21 0.94 0.52 - 1.71 0.84 
Educational Level      
primary or less 11 17    
Secondary 20 46 1.30 0.72 - 2.30 0.40 
Employment      
Employed 9 24    
unemployed/self-employed 22 39 0.76 0.40 - 1.40 0.39 
Income  
<= 1000 5 13  
> 1000 7 24 1.23 0.46 ‐ 3.30  0.68
Housing  
Inadequate 5 9  
Adequate 26 54 1.10 0.42 ‐ 1.97  0.81
Hiding medication  
Yes 2 1  
No 29 62 2.09 0.89 ‐ 4.90  0.25*
Travel time to clinic  
<= 30 minutes 17 35  
> 30 minutes 13 28 1.03 0.57 ‐ 1.87  0.92
Follow-up Adherence counseling  
Yes 9 22  
No 22 41 0.83 0.44 ‐ 1.59  0.57
Knowledge of HIV/AIDS and ART  
Inadequate 25 46  
Adequate 6 17 1.34 0.85 ‐ 1.54  0.42
First line 29 61  
Second line 2 2 1.35 0.50 ‐ 3.60  0.60*
Stage of Pregancy  
Antenatal 28 66  
Posnatal 24 70 1.17 0.62 ‐ 2.47  0.51
CD4 count  
< 250 9 14  
>=250 22 49 1.26 0.68 ‐ 2.34  0.47
Viral Load  
Detectable 8 9  
Undetectable 23 54 1.33 0.83 ‐ 2.10  0.17
Other medical conditions  
Yes 2 4  
No 29 59 1.01 0.31 ‐ 3.26  0.65*
Length of treatment  
 = < 1 year 0 1  
> 1 year 31 62 ‐ ‐  0.67*
Side Effects  
Recorded 0 1  
Not recorded 31 62 ‐ ‐  0.67*
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CHAPTER 6 
DISCUSSION, LIMITATIONS, GENERALIZABILITY, CONCLUSION AND   
RECOMMENDATIONS 
6.1 Discussion 
The use of HAART among pregnant woman has in recent years led to further  reductions 
in mother to child transmission to less than 2% in the regions of the world where it has 
been implemented (WHO, 2007). Lack of adherence to HAART treatment continues to 
be the major cause of higher than expected vertical transmission rates of the human 
immunodeficiency virus as well as treatment failure. The purpose of the study was to 
assess the level of adherence among women who initiated HAART treatment during 
pregnancy at research clinics in Botswana and are expected to continue their treatment 
indefinitely. To my knowledge, this is the first study to report on the assessment of 
adherence among women who initiated treatment during pregnancy in Botswana.  
 
Using the 6months pill count measurement we also found that 99% of participants have 
an “adequate” adherence level of 95% and above. The ultimate is for patients to take all 
their medication and achieve an “excellent” level of adherence of 100%. In this study 
adherence was also examined post-hoc using the 100% cut-off level. Using this 
classification, we found that 67% of the participants reached 100% adherence as 
measured by pill counts over the past 6 months.  This finding from a research setting 
could have resulted from intensive close monitoring of the women and more frequent 
study visit schedules. Before initiating treatment most of the women consented to 
unscheduled home visits by members of the study team and also identified adherence 
partners whose role was to remind them to take their medications as prescribed. 
 
Findings from this study are also consistent with a previous study in Botswana which 
reported “adequate” adherence to ART in the general population as high as 77% by pill 
counts and 96% by participants self report (Kgatlwane et al., 2006). Despite the concerns 
about low adherence which have been cited by those who question the feasibility of 
rapidly scaling up antiretroviral therapy programmes especially in resource poor settings 
(Stephens, Kaye & Corrah, 2004, Raboud, 2002), this study strengthens the existing 
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findings from other studies that have shown that it is possible to maintain high adherence 
in these settings. Mills et al., (2006) reported that self reported and pill count adherence 
rates in African settings were found to be higher than in North American settings, and 
noted that this may reflect a true higher adherence, or may reflect a greater desire by 
patients to report high adherence to health workers. Indirect evidence that high adherence 
levels in this study and by extension in Botswana are real is that the mother to child 
vertical transmission (MTCT) rates of HIV in Botswana are very low at less than 4% 
(Ministry of Health, 2007) and in this study they were extremely low at 0.6% for infants 
born to women enrolled in this cohort. 
 
Higher levels of adherence obtained in this study may reflect the clinical trial setting in 
which the women were being followed.  As in all research settings the quality of care in 
this setting is likely to be higher than what obtains in the public sector and probably is 
better than that experienced in the private sector as well. The frequency of contact with 
the health workers was also higher and is highly likely to have contributed to the higher 
adherence level, especially given that at each visit adherence monitoring was conducted. 
Alternatively the very high adherence rates could simply be an overestimate of adherence 
and as with all measures of adherence besides drug serum levels it is impossible to 
determine whether this is the case. However a synthesis of the comments above which all 
indicate that a high level of adherence is plausible, suggest that even if the pill count 
adherence is an overestimate it is still likely to be close to the actual adherence level in 
this population.   
 
Given that pregnant woman are generally required to attend health facilities for regular 
health checks, the contacts with the health care workers during the antenatal period in the 
public and private sector should also serve to reinforce medication adherence, which is 
likely to result in pregnant women taking their medications more religiously than other 
people on HAART. However, the finding of no significant difference between adherence 
during the antenatal period, immediate postnatal and late postnatal period (when 
breastfeeding would have ceased) suggests that the risk of viral transmission to the child 
during pregnancy or breastfeeding was not a significant added motivation for adherence 
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in this population. Alternatively since the adherence levels were high throughout all three 
periods it might suggest that this added motivation was not needed to achieve high 
adherence. When adherence is already high it is very difficult to assess the added effect 
of a promoter on adherence and hence the potential additive effect of desire to reduce 
vertical transmission is best assessed amongst a population where adherence levels are 
generally low. The plausibility of this is supported in the reports by Bardequez et al., 
(2008) & Vaz et al., (2007) who reported a higher antenatal adherence and lower 
adherence in the postnatal period among cohorts of US and Brazilian pregnant women, 
where overall adherence rates were lower than in this study. The other explanation for no 
difference in adherence levels between the antenatal and postnatal adherence periods is 
that the desire to prevent vertical transmission was present in both periods, as all the 
participants’ were required to breastfed for 6 months. This explanation would however be 
contradicted by the lack of difference in adherence levels between the antenatal/early 
postnatal and the late postnatal period as the participants did not breastfeed during the 
late postnatal period. In this regard it is worth noting that both the US and Brazil studies 
mentioned above were done amongst a non breastfeeding population. 
 
 This study showed a high level of adherence counselling with 99% having being 
formally counselled at least once, 70% of the participants having received more than one 
formal counselling session, almost all (99%) having received informal counselling during 
adherence monitoring and 99% of  participants satisfied with the level of counselling 
received (Figures 5.7 and 5.8). Since this counselling was provided to everyone it is 
likely that it affected the overall high level of adherence.  
 
Using the patient self report measurement we found a high degree of short term 
adherence to HAART among women in this population, with 100% of the patients 
reporting that they had 100% adherence during the last 7 days. It is possible that the 
participants told the research assistant what they thought she wanted to hear and hence an 
overestimate of adherence was obtained via this measurement. Lu et al., (2008) reported 
that self-recall measures of antiretroviral adherence vary greatly in recall time periods 
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and further suggested that over reporting was higher for 3 day and 7 day recall and more 
reflective for the 1month recall. 
 
During the interview participants may find it difficult or embarrassing to say that they 
missed their medication and therefore overestimate their adherence responses. Pill counts 
might therefore provide a better measure of adherence albeit with a caveat; they may 
overestimate adherence if the participant discards (or retains) the pills they are supposed 
to return to the clinic.  It seems probable that only a longitudinal analysis of adherence 
via regular serum drug assays or biochemical markers may allow justice to be done to the 
subject of assessing adherence at both patient and population levels. Based on reported 
pill count adherence, participants self reported adherence was way too high in this study 
and given that pill counts itself might be an overestimate, it is reasonable to say that 
adherence by self report could be a gross overestimate and pill count might be a better 
measure of adherence compared to self report in this study. Kgatlwane et al., (2006) had 
similar finding of higher adherence by self report compared to pill count in Botswana 
(96% and 75% respectively).  
 
This study also reported a high adherence to medication refill appointments across the 
scheduled pharmacy refill visits throughout the three different pregnancy stages. The 
mean adherence to refill appointments was 97.9% and decreased from 98.9% in the ANC 
period to 96.8% in the late postnatal period. Although Pharmacy refill appointments is a 
very coarse measure of adherence, as it can only determine if patients are inadequately 
adhering but cannot determine if they are adequately adhering since collecting drugs does 
not necessarily mean taking them as prescribed by the health care provider (Steiner & 
Prochazka, 1997), the low level of missed medication refills is consistent with and 
supports the veracity of the high level of adherence reported in this study using pill count.   
 
 Bivariate analysis showed no association between adherence by pill count and any of the 
potential factors commonly found associated with adherence by other studies. The 
possible explanations for these findings may include the following; the sample size was 
not large enough to detect associations which might truly exist in this study population.  
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Differential measurement bias with the possibility that some of the participants 
categorised as perfect or excellent (100%) adherence might not be so, due to the inherent 
pill count measurement error described above.  
The participants were very homogenous for several of the factors assessed due to the 
main study being a randomised clinical trial with strict inclusion and exclusion criteria. 
Because of this homogeneity a very large sample size would be required to find an 
association which might truly exist. For example there was no association of adherence 
with age and this might be due to all participants being 21 years or older, thus eliminating 
the younger women who would likely have very different adherence levels.  
 
The participants also had very similar adherence levels (uniformly high.) Adherence 
levels were so high that a bivariate analysis using adequate (>=95%) versus inadequate 
(<95%) adherence was not reported on. Instead I had to assess perfect or excellent 
(100%) adherence versus imperfect (<100%) adherence. Again, this homogeneity would 
require a very large sample to detect an association which might truly exist within the 
study population.  
 
Because this study assessed potential factors by comparing perfect or excellent (100%) 
adherence versus imperfect (<100%) adherence, it differs from other adherence studies 
which usually compared adequate versus inadequate adherence. So the factors associated 
with adequate adherence might in fact not be associated with excellent adherence, or 
more likely they might be only weakly associated with it.     
 
It might also be possible that the research clinic environment overrides or modifies the 
effect that these usually associated factors have on adherence, and thus acts as an effect 
modifier. This could happen in two ways. Directly by providing things which directly 
increases adherence such as excellent and ongoing adherence counseling. This might 
result in substantially increased adherence amongst all participants, and since adherence 
is increased in all the participants, the differences between sub-groups would be 
minimized. Secondly the research clinic might do this indirectly, for example by 
informally transmitting increased knowledge of ARVs and HIV, which the participants 
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could accrue due to the excellent service provided, frequent contact with the clinic, long 
service time per visit and increased rapport they have with the staff. This increased level 
of knowledge could then override the effect of several factors such as lack of general 
education, or low income, or lack of adequate housing for example and hence these and 
other related factors in this study are not associated with adherence as they were 
overridden. The above suggestions are mainly speculative though and would need to be 
confirmed or refuted by larger studies with more accurate and detailed measures of 
adherence.   
 
Patients were also asked to provide reasons for potentially missing their medication. 
Forgetfulness was the most cited reason (18%) followed by lack of access to pills at the 
time doses needed to be taken (13%). There were no reported problems with pill burden, 
side effects or not taking medications because of feeling better. Forgetting is one of the 
major reasons found in many studies for poor adherence to treatment. Some studies have 
reported that the important barriers to adherence namely; forgetfulness, lack of access to 
pills, feeling better and alcohol use; were consistent across multiple settings and countries 
(Walsh et al., 2001; Murphy et al., 2004; Kgatlwane et al.,2006; Mills et al., 2006). In 
Botswana patients on ART are required to identify an adherence partner and are 
facilitated to choose an adherence package that will enable them not to forget their 
medication.   
 
Most of the participants (97%) in this study were still on first line therapy (Table 5.6) and 
the majority of them have been on treatment for more than 1 year via the parent study. 
This indicates that there have been very few (3%) regimen failures among the women in 
the on-going follow-up period, although it is possible that a few of the subjects still on 
first line therapy are possibly failing and should have been transitioned to second line 
therapy. This high percentage of first line therapy, high degree  of knowledge of 
HIV/AIDS and ARVs as well as very low MTCT rates for this cohort (0.6%) reported by 
the parent study (Shapiro  et al., 2009), indirectly supports the veracity of the key finding 
of high levels of adherence.  
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6.2 Limitations 
• There is no gold standard for measuring adherence and each measure of 
adherence has its unique limitations. The limitations on measuring adherence 
which this study encountered were: the pill count measurement used in this study 
may have overestimated adherence as participants may have removed pills from 
their containers without actually swallowing them; participants might have told 
the health worker what they want to hear, hence self report adherence would have 
been overestimated; excellent pharmacy refill appointments do not necessarily 
translate into excellent adherence as participants might not have taken the 
medications as prescribed. 
• Patients were being followed in a research setting and therefore their disease 
characteristics are fairly homogeneous and they probably receive a higher quality 
of care than the women attending public sector clinics. The findings may 
therefore not be representative of what obtains in the general population.  
• Only pregnant women 21 years and older were included in the study. Anecdotal 
evidence suggests that younger pregnant women are less likely to adhere to their 
medications compared to older pregnant women.  
• The patients that have left the research clinics have been excluded from the 
sample as they would be difficult to track. These patients started transitioning to 
the local clinics since august 2008 on completion of 2 years of required follow up 
after delivery. The exclusion of them prevented the assessment of long-term 
adherence, but it is unlikely that their exclusion affected the medium-term (6 
months pill count) and short term (7 day recall) adherence, as they are likely to 
have had similar adherence levels at the equivalent time period in their treatment. 
This is because neither the recruitment nor management procedures changed 
during the study period.    
• Five participants did not consent to participation in the study. Without their 
consent it was not possible to review their patient files for the purpose of this 
study. It is possible that they may have had lower adherence levels as they were 
informed via the study information sheet that the study intended to investigate 
adherence. It is however unlikely that this would have introduced a substantial 
 
 
 
 
 50
selection bias, given their small numbers.   
• One person could not be reached as she did not attend the clinic during the 6 week 
data collection period. It is almost certain that this patient had lower adherence 
levels as she missed her medication refill appointment.  
6.3 Generalisability 
The results of this study may apply mainly to the study population. However it will also 
have a broader relevance especially among women who initiated antiretroviral therapy 
during pregnancy in urban and peri-urban communities in Botswana and countries with 
similar socioeconomic circumstances. However a rider to this is that generalisability 
would only obtain if in addition they received their treatment in a similarly supportive 
way to that which was provided at the research clinics.   
6.4 Conclusion 
A high level of adherence was found among pregnant women on HAART. Ninty-nine 
(99%) of the participants had optimal medium term adherence of 95% or higher using 6 
months pill count measurement. A 100% short term adherence was reported  by 
participant self report based on 1-day, 3-day and 7-day recall, this is likely to be an 
overestimate. Sixty-seven percent of the participants had an excellent level of medium 
term adherence of 100% by pill count and 99% of them had an adequate adherence level 
of 95% or more. Although this might also be an overestimate it is likely that it is close to 
the actual adherence level. There were no differences observed in adherence between the 
antenatal, immediate postnatal and late postnatal periods. The major reasons cited by 
participants for missing medications were forgetfulness and not having access to 
medication at the time required to take the doses. There was a high knowledge of ARVs 
and HIV/AIDS. Access to health services and counselling was rated very high by the 
participants, similarly for quality of care. There were no significant associations between 
adherence and socio-economic variables, access to health services and knowledge of 
ARVs and HIV/AIDS. The lack of association in this study between the factors usually 
known to be associated with adherence could possibly be due to small sample size, very 
high and similar levels of adherence obtained, homogeneity of the population and 
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potential effect modification present due to the high quality of care and close monitoring 
provided by the research clinic environment.   
 
6.5 Recommendations 
 
• Counselling on adherence and routine monitoring of adherence should be done   
regularly and frequently (e.g. monthly), as was done in the research clinics. 
• There is need to devise and provide a product for making the medication portable, 
such as a ‘travelling medicine holder’ and for strengthening the mechanisms for 
reminding patients to take their medications on a daily basis such as reminder 
alarms on cell phones. 
• Although there is high level of medium term adherence noted among pregnant 
women, a longitudinal study examining the long term postnatal rates of adherence 
and postnatal factors affecting adherence may be critical to understand what 
happens long after the women have given birth and are continuing with HAART.  
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APPENDIX 1: SAMPLE QUESTIONNAIRE 
Date------------------- 
Participant’s number---------------- 
A. Demographic and socio economic information 
1. Age in years?  ---------------------- 
2. Marital status? 
A= single 
B= married 
C= co-habiting 
D= divorced 
E= widowed 
3. What are your religious practices? 
A= Christianity 
B= Islam 
C= African traditional religion (worship of ancestors) 
D= Atheism (believe in no God) 
E= Other: ____________________ 
4. Educational level completed? _____________________ 
5. Employment status? 
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A= Employed 
B = Unemployed 
C= Self Employed 
6a. How much money do you earn per month from employment if employed or self 
employed? ______________________ 
6b. what other income do you have? 
Please list sources and amount earned from each source: _________________________ 
7. Has lack of food ever made you miss your medication? 
A= Yes 
B= No 
8a. How many people including yourself stay in your household/compound most of the 
time: ______________________________ 
8b. Do you have electricity in your house? 
A= Yes 
B= No 
8c: Do you have piped water in your compound? 
A= Yes 
B= No 
8d. Which of the following toilet facilities do you have in your home? 
A= indoor flush toilet 
B= Private pit latrine 
C= Shared pit latrines with other compounds 
D= No toilet facilities 
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E= Other (Please specify): _____________________ 
9a. Does anyone in your household know about your HIV status? 
A= Yes 
B= No 
9b. If yes, who? (Please list)__________________________________ 
9c. Does feeling that you have to hide your medications from those around you ever 
made you  miss your medications? 
A=Yes 
B= No 
9d. Do you have anyone at home to remind you to take your medications? 
A= Yes 
B= No 
10a. Do you take alcohol? (if yes answer 9b other wise go to 10) 
A= Yes 
B= No 
10b. Has taking alcohol ever made you miss your medication? 
A=Yes 
B=No 
B. Access to Health services 
11. Can you estimate how long it takes you to get to the clinic? ___________________ 
12. How do you come to the clinic? 
A=Walking 
B= Bus/taxi 
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C= own vehicle 
D= Order (please specify): ___________________ 
13. Do you lose any income during the time you attend this clinic? 
A=Yes 
B=No 
14a. Has your being on ARV resulted in increased expenditure? (if yes answer 13b,  
otherwise go to question 14). 
A=Yes 
B=No 
14b. What was the increased expenditure for? _____________________ 
14c. How much extra did you have to spend? (Please specify)______________________ 
 
C. Adequacy of Service and Level of Counselling 
15a. Were you counselled about adherence before or since you started treatment? (if yes 
answer 15b otherwise go to question 15) 
A= Yes 
B= No 
15b. How often did you receive adherence counselling after you started treatment? 
A= At every visit 
B= At some visits 
C= Never 
15c. How useful did you find the counselling sessions? 
A= Not useful 
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B= slightly useful 
C= Useful. 
D= Very useful. 
16a. Did you talk with the health worker about your experience of using your medicines? 
(side effects, perceived effects) 
A=Yes 
B= No 
If yes then answer 16b-d 
16b. Did the health worker ask you if you have missed a dose of your medication? 
A=Yes 
B= No 
16c. Did the health worker explain to you what the effects of missing a dose are? 
A=Yes 
B= No 
16d. Did the health worker ask if you are taking other medicines or traditional medicines? 
A=Yes 
B= No 
17. Did the health worker count your pill before giving you a new supply? 
A=Yes 
B= No 
18 How would you rate the overall quality of care and services you are receiving at this 
clinic? 
A= Poor 
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B= Fair 
C= Good 
D= Very good 
D. Knowledge and attitudes towards ARV’s and HIV/AIDS. 
19. What do think will happen to your health if you do not take your medications 
regularly? (Based on the response to each of the options below, give the following scores. 
1=strongly disagree, 2= disagree, 3=agree, 4= strongly agree. 5=uncertain; for use by 
research assistant only if patient cannot pick any of the other 4 options) 
 Question response 
19a Your health will get worse  
19b You may develop opportunistic infections  
19c Nothing will happen  
19d Your CD4 will decrease  
19e You may lose weight:  
19f You may develop diarrhoea  
19g Your viral load will increase  
 
20. What do you know about treatment for HIV infection? (Based on the response to each 
of the options below, give the following scores. 1=strongly disagree, 2= disagree,, 
3=agree, 4= strongly agree. 5=uncertain; for use by research assistant only if patient 
cannot pick any of the first 4 options) 
i) The disease has no cure for now and therefore i need to continue treatment forever: 
_____________ 
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ii) Treatment helps to prolong life: ______________________________ 
iii). Taking of ARV’s may result in experience of side effects like nausea, vomiting, 
hepatitis, low blood count and diarrhoea:_______________________ 
iv) Treatment helps to reduce the chances of transmission to the unborn and breast 
feeding infants: _________________________________ 
21. ARV’s work by suppressing viral load and increasing CD4 counts, do you agree? 
(Based on response, give the following scores. 1=strongly disagree, 2= disagree,, 
3=agree, 4= strongly agree. 5=uncertain; to be used by research assistant only if the 
patient cannot pick any of the first 4 options):_______________________ 
22. ARV’s can interact with other drugs including indigenous or traditional medications 
causing serious reaction? (Based on response, give the following scores. 1=strongly 
disagree, 2= disagree, 3=agree, 4= strongly agree. 3=uncertain. 5=uncertain; to be used 
by research assistant only if the patient cannot pick any of the first 4 
options):________________ 
 
23a. How do you feel about having to take medications everyday?(Please describe 
briefly):_________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
23b. Do you feel you can skip the medications for some days and still be healthy? 
A=Yes 
B=No 
Has any of the following made you miss your medications? 
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25. felt better 
A= Yes 
B= No 
26. Did not just feel like taking medications on that day? 
A=Yes 
B= No 
27. The pills were too many? 
A= Yes 
B= No 
28. Forgot 
A= Yes 
B= No 
29. Did not have pills with you at the time you needed to take them 
A=Yes 
B= No 
Self reported adherence: 
30a. Research assistant should ask patient and then cross out the medications the subject 
took in the past seven days using the table below: 
Name 
of 
Drug 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
 AM PM AM PM AM PM AM PM AM PM AM PM AM PM
 AM PM AM PM AM PM AM PM AM PM AM PM AM PM
 
 
 
 
 67
 AM PM AM PM AM PM AM PM AM PM AM PM AM PM
 AM PM AM PM AM PM AM PM AM PM AM PM AM PM
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APPENDIX 2: DATA EXTRACTION FORM FROM PARTICIPANT’S 
CLINICAL RECORDS. 
 
 
Date: _________________________ 
 
 
Participants Number: _____________ 
 
 
1. Current regimen: _________________________ 
 
 
Please circle one; i) first line; ii) second line; iii) third line. 
 
 
2. Length of time on treatment: ____________ 
 
 
3a. Please review medical records and complete the table below for ARV regimen: 
Name pill Number of pills 
taken per dose 
Number of 
times taken per 
day 
   
   
   
 
3b. Is there any other medical condition that patient is receiving treatment for? (Please 
specify):___________________________ 
3c.Please review medical records and enter into the table below the other medications 
patient is taking aside from ARV’s. 
 
 
 
 
 
 69
 
Name pill Number of pills 
taken per dose 
Number of 
times taken per 
day 
   
   
   
 
 
Adherence in the antenatal period. 
 
4a. Any missed medication refill appointment during pregnancy?   Circle Yes or No? 
 
If yes, number of times missed: ____________________________________ 
 
4b. Monthly Pill count records during pregnancy? (Please complete the table below) 
 
Month a b c D e f Total 
Number 
of pills 
dispensed 
at last 
visit 
       
Expected 
pills at 
current 
visit 
       
Returned 
pills at 
current 
visit 
       
Number 
of doses 
missed 
       
 
 
4c. Documentation of side effects. Circle Yes or No 
 
4d. CD4 during pregnancy (capture closest to delivery or at delivery):___________ 
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Date drawn: __________________ 
4e.Viral load during pregnancy (capture closest to delivery or at delivery):___________ 
Date drawn: __________ 
 
4f. WHO disease stage during pregnancy: __________________________ 
 
 
Adherence in the early post natal period (including breast feeding) 
 
5a. Any missed medication refill appointment during the first six months after delivery?   
Circle Yes or No? 
 
If yes, number of times missed: ____________________________________ 
 
5b. Pill count records in the first 6months after delivery? (Please complete the table 
below) 
 
Month a b c D e f Total 
Number 
of pills 
dispensed 
at last 
visit 
       
Expected 
pills at 
current 
visit 
       
Returned 
pills at 
current 
visit 
       
Number 
of doses 
missed 
       
 
 
5c. Documentation of side effects. Circle Yes or No 
 
5d. CD4 at six months after delivery (or nearest time point): __________________ 
Date drawn: ________________ 
 
5e. viral load at six months after delivery (or nearest time point): ______________ 
Date drawn: __________ 
 
5f. WHO disease stage in the first 6months after delivery: __________________ 
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Adherence in the late post natal period (review past six months). 
 
5a. Any missed medication refill appointment in the last 6months?   Circle Yes or No? 
 
If yes, number of times missed: ____________________________________ 
 
5b. Pill count records in the last 6months? (Please complete the table below) 
 
Month a b c D e f Total 
Number 
of pills 
dispensed 
at last 
visit 
       
Expected 
pills at 
current 
visit 
       
Returned 
pills at 
current 
visit 
       
Number 
of doses 
missed 
       
 
5c. Documentation of side effects. Circle Yes or No 
 
5d. Most recent CD4:__________________ Date drawn: _______________ 
 
5e. Most recent viral load: ______________ Date drawn: _______________ 
 
5f. Current WHO disease stage: ____________________________________ 
 
 
 
 
 
 
 
 
 
 72
APPENDIX 3: ADULT/ADOLESCENT WHO CLINICAL STAGING 
 
Clinical Stage 1: Asymptomatic 
Asymptomatic 
Persistent generalized lymphadenopathy 
 
Clinical Stage 2: Moderate Disease 
Unexplained moderate weight loss <10% of baseline weight 
Recurrent upper respiratory infections (sinusitis, otitis media, tonsillitis, pharyngitis) 
Mono-dermatomal VZV 
Recurrent oral ulceration 
Papular pruritic eruptions 
Seborrheic dermatitis 
Fungal nail infections 
 
Clinical Stage 3: Advanced Disease 
Unexplained weight loss >10% of baseline 
Unexplained chronic diarrhea for more than one month 
Unexplained persistent fever (>37.5C, intermittent or constant) for more than one month 
Persistent oral candidiasis 
Oral hairy leukoplakia 
Pulmonary TB 
Severe bacterial infections (e.g., pneumonia, meningitis, PID,* bone/joint infection, 
bacteremia) 
Multi-dermatomal, recurrent mono-dermatomal, or ophthalmic VZV* 
Necrotizing ulcerative gingivitis, peridontitis, stomatitis 
Unexplained anemia (<8gm%), neutropenia (<500/μL), and/or thrombocytopenia 
(<50,000/μL) 
*Not part of international WHO staging, but added as frequent Botswana-specific HIV-
related “advanced” conditions meriting HAART 
 
Clinical Stage 4: Severe disease 
HIV wasting syndrome 
Pneumocystis pneumonia 
Recurrent severe bacterial pneumonia 
Chronic HSV infection (orolabial, genital, rectal for more than one month or visceral at 
any site) 
Esophageal candidiasis (or candidiasis of trachea, bronchi, or lungs) 
Extra-pulmonary TB 
Kaposi’s sarcoma 
CMV (retinitis or infection of other organs) 
CNS toxoplasmosis 
HIV encephalopathy 
Extrapulmonary cryptococcosis, including meningitis 
Disseminated non-TB mycobacterial infection 
Progressive multifocal leukoencephalopathy 
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Chronic cryptosporidiosis, isosporiasis 
Disseminated mycosis 
Recurrent septicemia 
Lymphoma (cerebral or non-Hodgkin's) 
Invasive cervical carcinoma 
Atypical disseminated leishmaniasis 
Symptomatic HIV-associated nephropathy and cardiomyopathy 
 
 
FOOT NOTE: 
i. A single, non-recurrent episode of mono-dermatomal VZV infection is a 
stage 2 condition. Recurrent mono-dermatomal VZV, a single episode of 
multi-dermatomal VZV, or ophthalmic VZV should be regarded as stage 3 
conditions. 
ii. Recurrent severe PID is a WHO stage 3 condition. 
 
 
 
Adapted from: Botswana National HIV/AIDS Treatment Guidelines November 2008 
Version. 
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APPENDIX 4: SAMPLE PILL CALENDAR 
Name _____________________________    BID ________________________          Clinic phone# _______________________ 
Start Date: Weekday: Letsatsi: Combivir
 
_____ AM 
Nevirapine 
 
_____ AM 
Combivir
 
_____ PM 
Nevirapine
 
_____ PM  
 Sunday Tshipi
 Monday Mosupologo
 Tuesday Labobedi
 Wednesday Laboraro
 Thursday Labone
 Friday Labotlhano
 Saturday Matlhatso
 
 Sunday Tshipi
 Monday Mosupologo
 Tuesday Labobedi
 Wednesday Laboraro
 Thursday Labone
 Friday Labotlhano
 Saturday Matlhatso
 
 Sunday Tshipi
 Monday Mosupologo
 Tuesday Labobedi
 Wednesday Laboraro
 Thursday Labone
 Friday Labotlhano
 Saturday Matlhatso
 
 Sunday Tshipi
 Monday Mosupologo
 Tuesday Labobedi
 Wednesday Laboraro
 Thursday Labone
 Friday Labotlhano
 Saturday Matlhatso
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   APPENDIX 5: ETHICS APPROVAL UNIVERSITY OF THE WESTERN CAPE 
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